Évaluation de la fibromyalgie secondaire à la polyarthrite rhumatoïde ou la spondylarthrite [Assessment of secondary fibromyalgia in patients with rheumatoid arthritis or spondylarthritis]
Fiche du document
16 mars 2022
- doi: 10.53738/REVMED.2022.18.773.477
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2022.18.773.477
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/35306768
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_B3C68A4A7B524
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Aches Joints--Inflammation ArthritidesCiter ce document
P. Ming Azevedo et al., « Évaluation de la fibromyalgie secondaire à la polyarthrite rhumatoïde ou la spondylarthrite [Assessment of secondary fibromyalgia in patients with rheumatoid arthritis or spondylarthritis] », Serveur académique Lausannois, ID : 10.53738/REVMED.2022.18.773.477
Métriques
Partage / Export
Résumé
Pain is one of the main factors assessed in most of the scores used to measure activity in rheumatoid arthritis (RA) and spondylo arthritis (SpA). However, the experience of pain is complex, subjective and influenced by many factors. Fibromyalgia (FM) is present in 16-38% of patients with inflammatory rheumatic diseases (IRD) and has been shown to significantly increase indices of disease activity, often preventing an adequate response to immunosuppressive treatments. Recognition of secondary FM is important to avoid overtreatment. This article explores the relationship between FM and IRD, and how to optimise the assessment and treatment of one in the presence of the other.